The Week of May 13 in Review

The week of May 13 in review, featuring stories and videos on cabozantinib in medullary thyroid cancer, biomarkers in prostate cancer, and SAR302503 in myelofibrosis.

Dr. Morris on Radium-223 Plus Docetaxel in Patients With Bone Metastasis From CRPC

A Guide to ASCO 2013: Key Targeted Trials

ASCO Highlights 7 Studies in Advanced Release

ASCO 2013 Abstract Roundup

Monica Fradkin on Treating With Chemotherapy and Biotherapy

Numerous Drug Classes Studied for Use in Follicular and Other Lymphomas

Dr. Debu Tripathy Describes Intratumoral Heterogeneity

Researchers Identify How Nongenetic Mechanisms of Cancer Cell Diversity Can Affect Treatment Response

Dr. Sherman Comments on Cabozantinib and Vandetanib in Medullary Thyroid Cancer

Radium RA 223 dichloride (Xofigo) has been approved by the FDA for the treatment of symptomatic metastatic castration-resistant prostate cancer (mCRPC) that has spread to the bones but not to any other organs.Michael J. Morris, MD, medical oncologist, Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, discusses a phase I/IIa study looking at radium-223 with docetaxel in patients with bone metastasis from castration-resistant prostate cancer.In advance of the 2013 ASCO annual meeting,Targeted Therapy Newsspoke with this year’s chair of the Scientific Program Committee, Douglas Yee, MD, about key presentations and sessions that attendees can expect.ASCO highlighted studies on treatment with ipilimumab and nivolumab in advanced melanoma, radiation in NSCLC, and idelalisib in chronic lymphocytic leukemia.Abstracts published in the Annual Meeting Proceedings Part I featuring late-stage data on ibrutinib, eribulin, regorafenib, sipuleucel-T, lambrolizumab, palbociclib, and more.Monica Fradkin, RN, BSN, MPH, OCN, Oncology Nursing Education Coordinator, Yale School of Nursing, Smilow Cancer Hospital at Yale-New Haven, discusses treating patients with chemotherapy and biotherapy.Follicular lymphoma is characterized by repeated treatment responses and then relapses, and researchers will need to generate a growing list of drug choices to keep pace with patients’ needs.Debu Tripathy, MD, Co-Leader, Women's Cancer Program, Norris Comprehensive Cancer Center, University of Southern California, describes intratumoral heterogeneity in patients with breast cancer.A new study suggests that even tumor cells with a common genetic background can display functional heterogeneity.